September 22nd 2023
The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
September 14th 2023
September 12th 2023
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
23rd Annual International Congress on the Future of Breast Cancer® West
Register Now!
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
25th Annual International Lung Cancer Congress®
Register Now!
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Durvalumab shows promise as perioperative addition for muscle-invasive urothelial carcinoma
September 5th 2023Adding perioperative durvalumab to standard care for patients with resectable muscle-invasive urothelial carcinoma demonstrated promising event-free and overall survival rates in a phase 2 trial.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
Dr. Emamekhoo on how his institute is addressing the cancer drug shortage
July 19th 2023“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.
Dr. Kamran on current research into predictive factors of response to bladder-preserving treatment
June 27th 2023"There are a lot of exciting data that are coming out, and, of course, a lot of physicians and physician-scientists [who] are interested in these questions, and we’re working on that," says Sophia C. Kamran, MD.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.